This article was originally published in The Gray Sheet
Executive SummarySubmits premarket approval application for Telio-Derm wound healing agent for the treatment of chronic dermal ulcers associated with diabetes. A study supporting the PMA filing showed a "fourfold increase in the number of ulcers completely healed in the Telio-Derm group compared to the control group," according to the company. Telios also plans to apply its technology to the treatment of ophthalmic and other types of severe and chronic dermal wounds.
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.